LAVA Therapeutics N.V. Overview
Pro stress-test →LAVA Therapeutics is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.
Strategic Profile
Pro stress-test →LAVA Therapeutics was acquired by XOMA Royalty Corporation in November 2025. The company continues to enroll in the Phase 1 clinical study evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and supports partnerships with Pfizer and Johnson and Johnson. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers including LAVA 1266, targeting CD123+ cancers; PF-08046052, targeting EGFR; and JNJ-89853413, targeting hematological cancers.
Competitive Landscape
Pro stress-test →LAVA competes in the immuno-oncology space with companies developing bispecific antibodies and T cell engagers. Key differentiators include its proprietary Gammabody platform targeting gamma-delta T cells (less explored than alpha-beta T cells) and partnerships with major pharma including Pfizer and Johnson & Johnson. Competitors include broader immuno-oncology players focused on CAR-T, TCR-engineered, and conventional bispecific approaches.
Industry Context
LAVA Therapeutics N.V. operates in Biotechnology - Clinical-Stage Immuno-Oncology.
Key facts
Founded: 2016 · Headquarters: Utrecht, Netherlands · Employees: 10 (post-acquisition) · Revenue: $11.98M (2024)